The investment round saw participation from several notable firms including Deep Track Capital, Access Biotechnology, Qatar Investment Authority, Cormorant Asset Management, Sanofi Ventures, Rock Springs Capital, UPMC Enterprises, and Kern Capital, alongside continued support from existing investors such as Westlake Village BioPartners, Foresite Capital, 5AM Ventures, and Alexandria Venture Investments.
As part of the financing, Kevin Raidy of Blue Owl Capital will join Latigo's board of directors. The company aims to accelerate the development of its portfolio of non-addictive pain treatments, addressing the urgent need for alternatives to opioid pain medications.